Why Intuitive Surgical Stock Dropped This Week

Intuitive Surgical reported solid second-quarter results. Worldwide procedures using its da Vinci robotic system grew 16% year over year, and revenue climbed 19% to $2.9 billion. Adjusted earnings per share of $2.80 beat Wall Street's estimate of $2.50.

Despite the beat, the stock dropped 14% this week. The reason? Management kept its full-year procedure growth guidance at 13.5% to 15.5%, the same range issued earlier. By not raising guidance after a strong quarter, the company essentially forecast slower growth for the rest of the year.

Wall Street analysts responded by cutting price targets on the stock. Many investors sold shares, fearing that the company's rapid expansion is cooling off.

Intuitive Surgical is the leader in robotic-assisted surgery, with over 11,700 da Vinci systems installed worldwide. Its Ion platform for lung biopsies is also growing quickly, with a 21% increase in installed base.

Intuitive Surgical's stock is priced for perfection. With a high valuation, any hint of slowing growth can trigger a sharp sell-off. The company's decision to maintain rather than raise guidance suggests that the pandemic-era surge in surgical procedures is normalizing.

However, the long-term story remains intact. Robotic surgery adoption is still in its early stages, and Intuitive's installed base and recurring revenue from instruments and services provide a strong moat. The 14% drop may present a buying opportunity for patient investors.

Competitors like Medtronic and Johnson & Johnson are developing rival systems, but Intuitive's vast installed base and continuous innovation give it a significant edge. The key question is whether growth will re-accelerate or continue to decelerate.

For now, the market is punishing the stock for not exceeding already high expectations. But if procedure growth stabilizes or picks up, the sell-off could prove overdone.